Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases Date: September 27, 2010 Client: Amira Pharmaceuticals, Inc. Summary: San Diego, CA - September 27, 2010 -- Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist. If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.
		Data from Multiple Clinical Trials of OrbusNeich’s Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010 Date: September 25, 2010 Client: OrbusNeich Summary: WASHINGTON, Sept. 25, 2010 – OrbusNeich today announced that clinical trial results highlighting the company’s Genous Bio-engineered R stent and its endothelial progenitor cell (EPC) capture technology across challenging patient subsets were presented during a symposium titled “EPC Capture Technology: from Genous to Combo” at Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington.
		Stem Cells That Save Big Pharma a Bundle Date: September 23, 2010 Client: Cellular Dynamics International Summary: It's a frustrating and expensive pitfall for pharmaceutical companies: discovering late in the game that a promising new drug has side effects in humans that never surfaced in the laboratory or during earlier trials in animals. That kind of setback sends scientists back to the lab—or even prompts a company to shut down a multimillion-dollar drug development program. Researchers at Roche Holding, Pfizer (PFE), and GlaxoSmithKline (GSK) hope to use human tissue created from stem cells to reduce such mishaps.
		Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. Date: September 23, 2010 Client: Reata Pharmaceuticals Summary: ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23, 2010 -- Abbott and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD).
		Regulus Therapeutics Secures Additional Patents on microRNA Therapeutics for the Treatment of Hepatitis C Virus (HCV) Infection Date: September 23, 2010 Client: Regulus Therapeutics Inc. Summary: La Jolla, Calif., September 23, 2010 – Regulus Therapeutics Inc. announced today that the European Patent Office (EPO) and United States Patent and Trademark Office (USPTO) have recently granted claims for microRNA-122 therapy in hepatitis C viral (HCV) infections. The EPO issued a Notice of Intent to Grant for an application in the ‘Sarnow’ patent series (European Patent Application No. 05749437.9) for claims covering the use of an antisense inhibitor of miR-122 for the treatment of HCV infection and related conditions, either alone or in combination with other HCV therapeutic agents. Additionally, the USPTO has recently allowed claims in a continuation application in the Sarnow patent series (US Serial No. 11/953,705), directed to methods of reducing HCV viral genome amount with an antisense inhibitor of miR-122 in combination with other HCV therapeutic agents. The Sarnow patent series, owned by Stanford University and licensed to Regulus, relates to the discovery and development of therapeutic products for HCV infection by inhibiting the liver-specific microRNA known as miR-122.
		S*BIO Announces US$5 Million Investment by Mitsui Ventures Date: September 23, 2010 Client: S*BIO Pte Ltd Summary: SINGAPORE, Sept. 23, 2010 - S*BIO Pte Ltd today announced a US$5 million investment by Mitsui Ventures that will support the continued development of S*BIO’s clinical programs.
		Amira Pharmaceuticals - 2010 Fierce 15 Date: September 15, 2010 Client: Amira Pharmaceuticals, Inc. Summary: The Scoop: The management at Amira knows how to ration its venture cash. Working with a mere $28 million from four funds since it was founded five years ago, the developer struck a partnership in 2008 with GlaxoSmithKline that has helped fuel its in-house work. And CEO Bob Baltera, a savvy Amgen vet, says the biotech is oh-so-close to signing its second big pact that will gin fresh cash flow as they continue to work on their own programs.
		Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotech’s Annual Fierce 15 Date: September 15, 2010 Client: Amira Pharmaceuticals, Inc. Summary: San Diego, CA - September 15, 2010 -- Amira Pharmaceuticals, Inc. today was named one of the most promising biotech companies by FierceBiotech through its annual list, the Fierce 15.
		Alder Biopharmaceuticals - 2010 Fierce 15 Date: September 15, 2010 Client: Alder Biopharmaceuticals Inc. Summary: The Scoop: The conventional wisdom in biotech holds that startups must always gather up a group of venture backers before they start hiring a crew. But the news must never have made it to CEO Randall Schatzman, PhD, and his core team at Alder. They used their credit cards and borrowed office space to bootstrap Alder before roping in some seed capital. And they never looked back.
		FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15 Date: September 15, 2010 Client: Alder Biopharmaceuticals Inc. Summary: BOTHELL, Wash., September 15, 2010 – Alder Biopharmaceuticals Inc. today announced FierceBiotech has designated it one of the top private biotech biotech companies and placed it on the annual Fierce 15.
		Data from Clinical Trials Show Pluristem’s Placenta-Derived Cell Therapy is Safe and Improves Quality of Life and Efficacy Measurements in Patients With Critical Limb Ischemia Date: September 14, 2010 Client: Pluristem Therapeutics Inc. Summary: HAIFA, ISRAEL --(Business Wire)-- Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today reported that data from clinical trials show the Company’s placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).
		Cempra Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference 2010 Date: September 14, 2010 Client: Cempra Pharmaceuticals Inc. Summary: CHAPEL HILL, N.C., Sept. 14 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Stifel Nicolaus Healthcare Conference 2010 at 10:20 a.m. EDT, September 16, 2010, at the Four Seasons Hotel in Boston. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTATM (sodium fusidate, formerly CEM-102) for the oral treatment of gram positive pathogens including MRSA.
		Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting Date: September 13, 2010 Client: Arena Pharmaceuticals, Inc. Summary: SAN DIEGO, Sept. 13, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will host a conference call and webcast on Friday, September 17, 2010, at 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time) following the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting. The committee is scheduled to meet on September 16, 2010, to review the lorcaserin New Drug Application (NDA). Lorcaserin, which Arena discovered and has developed, is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese or patients who are overweight (Body Mass Index > 27) and have at least one weight-related co-morbid condition.
		Professor Leroux from ETH receives the Debiopharm Life Sciences Award 2010 Date: September 2, 2010 Client: Debiopharm Group™ Summary: Lausanne, Switzerland – September 2, 2010 - Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, today announced that the ‘Debiopharm Life Sciences Award 2010’ went to Professor Jean-Christophe Leroux for his innovative research on polymer chemistry, nanotechnology and pharmaceutical sciences to yield novel drug therapies. This year, the theme for the Award was “Drug Delivery and Pharmaceutical Technology”. Professor Leroux is an expert in galenic studies from the Swiss Federal Institute of Technology (ETH) in Zürich. He and his institute received CHF 100’000. Funded by Debiopharm, the ceremony took place at the EPFL (Ecole Polytechnique Fédérale de Lausanne) during the EPFL School of Life Sciences Symposium entitled “Engineering Life”.
		MorphoSys Initiates Program Against Drug-Resistant MRSA Infections Date: September 2, 2010 Client: MorphoSys AG Summary: MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today a new proprietary development program against novel infectious disease targets. As part of this initiative, MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics, providing access to novel target molecules associated with Staphylococcus aureus infections including MRSA (methicillin-resistant S. aureus). MorphoSys will generate antibodies using its proprietary HuCAL PLATINUM antibody library which Absynth will test in relevant disease models. MorphoSys will be solely responsible for the development and partnering of the resulting compounds. Absynth will receive an upfront payment and is eligible for development-dependent milestone payments and royalties. Further financial details were not disclosed.